{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:12Z","timestamp":1791302472241,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T00:00:00Z","timestamp":1038268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T00:00:00Z","timestamp":1038268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1038\/sj.leu.2402775","type":"journal-article","created":{"date-parts":[[2002,11,28]],"date-time":"2002-11-28T11:59:38Z","timestamp":1038484778000},"page":"2349-2357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs"],"prefix":"10.1038","volume":"16","author":[{"given":"AJ","family":"Tipping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FX","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Zafirides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JM","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JV","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,11,26]]},"reference":[{"key":"BF2402775_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D . Induction of chronic mye-logenous leukemia in mice by the P210bcr\/abl gene of the Phila-delphia chromosome Science 1990 247: 824\u2013830","journal-title":"Science"},{"key":"BF2402775_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 1990 247: 1079\u20131082","journal-title":"Science"},{"key":"BF2402775_CR3","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100\u2013104","journal-title":"Cancer Res"},{"key":"BF2402775_CR4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia Blood 2000 96: 3343\u20133356","journal-title":"Blood"},{"key":"BF2402775_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031\u20131037","journal-title":"N Engl J Med"},{"key":"BF2402775_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038\u20131042","journal-title":"N Engl J Med"},{"key":"BF2402775_CR7","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MWN Deininger","year":"1997","unstructured":"Deininger MWN, Goldman JM, Lydon NB, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells Blood 1997 90: 3691\u20133698","journal-title":"Blood"},{"key":"BF2402775_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 1996 2: 561\u2013566","journal-title":"Nat Med"},{"key":"BF2402775_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","volume":"23","author":"C Gambacorti-Passerini","year":"1997","unstructured":"Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di NM, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB . Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis Blood Cells Mol Dis 1997 23: 380\u2013394","journal-title":"Blood Cells Mol Dis"},{"key":"BF2402775_CR10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 2000 96: 1070\u20131079","journal-title":"Blood"},{"key":"BF2402775_CR11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 2000 95: 1758\u20131766","journal-title":"Blood"},{"key":"BF2402775_CR12","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines Blood 2000 95: 3498\u20133505","journal-title":"Blood"},{"key":"BF2402775_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293: 876\u2013880","journal-title":"Science"},{"key":"BF2402775_CR14","first-page":"435a","volume":"98","author":"S Kreil","year":"2001","unstructured":"Kreil S, Muller MC, Lahaye T, La Rosee P, Corbin AS, Schoch C, Cross NCP, Berger U, Rieder H, Druker BJ, Gschaidmeier H, Hehlmann R, Hochhaus A . Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy Blood 2001 98: 435a","journal-title":"Blood"},{"key":"BF2402775_CR15","volume-title":"The Leukemia\u2013Lymphoma Cell Line Facts Book","author":"HG Drexler","year":"2000","unstructured":"Drexler HG . The Leukemia\u2013Lymphoma Cell Line Facts Book Academic Press: London 2000"},{"key":"BF2402775_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984 22: 27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"BF2402775_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/sj.cdd.4400400","volume":"5","author":"S Dan","year":"1998","unstructured":"Dan S, Naito M, Tsuruo T . Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of Cell Death Differ 1998 5: 710\u2013715","journal-title":"Cell Death Differ"},{"key":"BF2402775_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y . In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 2001 97: 1999\u20132007","journal-title":"Blood"},{"key":"BF2402775_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.leu.2402041","volume":"15","author":"J Topaly","year":"2001","unstructured":"Topaly J, Zeller WJ, Fruehauf S . Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells Leukemia 2001 15: 342\u2013347","journal-title":"Leukemia"},{"key":"BF2402775_CR20","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","volume":"96","author":"JT Thiesing","year":"2000","unstructured":"Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ . Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells Blood 2000 96: 3195\u20133199","journal-title":"Blood"},{"key":"BF2402775_CR21","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V96.6.2246","volume":"96","author":"G Fang","year":"2000","unstructured":"Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN . CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood 2000 96: 2246\u20132253","journal-title":"Blood"},{"key":"BF2402775_CR22","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","volume":"86","author":"S O'Brien","year":"1995","unstructured":"O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M . Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase Blood 1995 86: 3322\u20133326","journal-title":"Blood"},{"key":"BF2402775_CR23","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","volume":"93","author":"S O'Brien","year":"1999","unstructured":"O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M . Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia Blood 1999 93: 4149\u20134153","journal-title":"Blood"},{"key":"BF2402775_CR24","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S . Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia J Clin Oncol 2000 18: 3513\u20133521","journal-title":"J Clin Oncol"},{"key":"BF2402775_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0006-291X(68)90266-0","volume":"33","author":"HL Elford","year":"1968","unstructured":"Elford HL . Effect of hydroxyurea on ribonucleotide reductase Biochem Biophys Res Commun 1968 33: 129\u2013135","journal-title":"Biochem Biophys Res Commun"},{"key":"BF2402775_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman JU . Cytokine therapeutics: lessons from interferon alpha Proc Natl Acad Sci USA 1994 91: 1198\u20131205","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402775_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1006\/bbrc.1997.7760","volume":"240","author":"P Gutierrez","year":"1997","unstructured":"Gutierrez P, Delgado MD, Richard C, Moreau-Gachelin F, Leon J . Interferon induces up-regulation of Spi-1\/PU.1 in human leukemia K562 cells Biochem Biophys Res Commun 1997 240: 862\u2013868","journal-title":"Biochem Biophys Res Commun"},{"key":"BF2402775_CR28","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood.V98.13.3864","volume":"98","author":"AJ Tipping","year":"2001","unstructured":"Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV . Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 2001 98: 3864\u20133867","journal-title":"Blood"},{"key":"BF2402775_CR29","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"C Barthe","year":"2001","unstructured":"Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163","journal-title":"Science"},{"key":"BF2402775_CR30","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"A Hochhaus","year":"2001","unstructured":"Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163","journal-title":"Science"},{"key":"BF2402775_CR31","first-page":"770a","volume":"98","author":"NP Shah","year":"2001","unstructured":"Shah NP, Nicoll JM, Gorre ME, Paquette R, Ford J, Sawyers CL . Resistance to Gleevec: sequence analysis reveals a spectrum of BCR\/ABL kinase domain mutations in both acquired- and de novo-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis Blood 2001 98: 770a","journal-title":"Blood"},{"key":"BF2402775_CR32","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP . High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 2002 99: 3472\u20133475","journal-title":"Blood"},{"key":"BF2402775_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 2002 359: 487\u2013491","journal-title":"Lancet"},{"key":"BF2402775_CR34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","volume":"99","author":"WK Hofmann","year":"2002","unstructured":"Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002 99: 1860\u20131862","journal-title":"Blood"},{"key":"BF2402775_CR35","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","volume":"100","author":"RR Hoover","year":"2002","unstructured":"Hoover RR, Mahon FX, Melo JV, Daley GQ . Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336 Blood 2002 100: 1068\u20131071","journal-title":"Blood"},{"key":"BF2402775_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1046\/j.1365-2141.2000.02056.x","volume":"109","author":"J Braess","year":"2000","unstructured":"Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W . Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine Br J Haematol 2000 109: 388\u2013395","journal-title":"Br J Haematol"},{"key":"BF2402775_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 1999 57: 727\u2013741","journal-title":"Biochem Pharmacol"},{"key":"BF2402775_CR38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.V91.5.1533","volume":"91","author":"GI Rodriguez","year":"1998","unstructured":"Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK . A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea Blood 1998 91: 1533\u20131541","journal-title":"Blood"},{"key":"BF2402775_CR39","first-page":"1403","volume":"70","author":"N Savaraj","year":"1986","unstructured":"Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, Loo TL . Clinical pharmacology of homoharringtonine Cancer Treat Rep 1986 70: 1403\u20131407","journal-title":"Cancer Treat Rep"},{"key":"BF2402775_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7326\/0003-4819-96-5-549","volume":"96","author":"JU Gutterman","year":"1982","unstructured":"Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z . Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients Ann Intern Med 1982 96: 549\u2013556","journal-title":"Ann Intern Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402775","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:49:54Z","timestamp":1648763394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,26]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["BF2402775"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402775","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,26]]},"assertion":[{"value":"12 July 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}